These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33537176)

  • 1. Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer.
    Martinez M; Kim S; St Jean N; O'Brien S; Lian L; Sun J; Verona RI; Moon E
    Oncoimmunology; 2021 Jan; 10(1):1873607. PubMed ID: 33537176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
    Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
    Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade.
    Roussel M; Le KS; Granier C; Llamas Gutierrez F; Foucher E; Le Gallou S; Pangault C; Xerri L; Launay V; Lamy T; Tartour E; Olive D; Fest T
    Blood Adv; 2021 Apr; 5(7):1816-1829. PubMed ID: 33787861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
    Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
    Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of immune checkpoint blockade on antigen-specific CD8
    Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
    Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer.
    Lu X; Liu J; Cui P; Liu T; Piao C; Xu X; Zhang Q; Xiao M; Liu X; Wang Y; Yang L
    Am J Cancer Res; 2018; 8(8):1564-1575. PubMed ID: 30210924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes.
    Trivedi P; Jhala G; De George DJ; Chiu C; Selck C; Ge T; Catterall T; Elkerbout L; Boon L; Joller N; Kay TW; Thomas HE; Krishnamurthy B
    Front Immunol; 2024; 15():1370907. PubMed ID: 38533515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short Communication: Metformin Reduces CD4 T Cell Exhaustion in HIV-Infected Adults on Suppressive Antiretroviral Therapy.
    Shikuma CM; Chew GM; Kohorn L; Souza SA; Chow D; SahBandar IN; Park EY; Hanks N; Gangcuangco LMA; Gerschenson M; Ndhlovu LC
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):303-305. PubMed ID: 31731885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of Cbl-b inhibits CD8
    Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint markers and anti-CD20-mediated NK cell activation.
    Wang Z; Weiner GJ
    J Leukoc Biol; 2021 Oct; 110(4):723-733. PubMed ID: 33615552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased co-expression of PD1 and TIM3 is associated with poor prognosis and immune microenvironment heterogeneity in gallbladder cancer.
    He X; Peng Y; He G; Ye H; Liu L; Zhou Q; Shi J; Fu S; Wang J; Zhou Z; Li W
    J Transl Med; 2023 Oct; 21(1):717. PubMed ID: 37828574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional and molecular characterization of PD1
    Lipp JJ; Wang L; Yang H; Yao F; Harrer N; Müller S; Berezowska S; Dorn P; Marti TM; Schmid RA; Hegedüs B; Souabni A; Carotta S; Pearson MA; Sommergruber W; Kocher GJ; Hall SRR
    Oncoimmunology; 2022; 11(1):2019466. PubMed ID: 35154905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
    Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.
    Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.